GL Pharma Vilnius, UAB - financials and debts

Company age: 19 y. 10 mo.

Update

GL Pharma Vilnius - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 812,029 898,749 905,071 917,054 1,004,910 1,101,340 1,483,931 1,580,164
Profit before tax 30,184 42,782 45,317 43,425 48,053 16,822 108,511 73,293
Net profit 20,618 34,170 36,828 35,237 38,756 10,947 89,761 58,888
Equity 83,030 117,200 154,028 189,265 228,021 238,968 328,729 387,617
Liabilities 92,516 42,779 65,400 75,736 57,406 84,054 110,892 110,891
Non-current assets 2,948 1,912 8,447 6,449 4,875 5,341 3,109 2,766
Current assets 168,225 153,794 210,475 257,831 279,769 325,685 431,889 487,151
Total assets 171,173 155,706 218,922 264,280 284,644 331,026 434,998 489,917
Taxes paid
Social insurance contributions - - - - - 60,515 64,109 57,469
Financial indicators
Revenue change y/y +2.2% +10.7% +0.7% +1.3% +9.6% +9.6% +34.7% +6.5%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 12.0% 21.9% 16.8% 13.3% 13.6% 3.3% 20.6% 12.0%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 24.8% 29.2% 23.9% 18.6% 17.0% 4.6% 27.3% 15.2%
Profit margin Net profit margin. Shows the overall profitability of the company. 2.5% 3.8% 4.1% 3.8% 3.9% 1.0% 6.0% 3.7%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 3.7% 4.8% 5.0% 4.7% 4.8% 1.5% 7.3% 4.6%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 1.1 0.4 0.4 0.4 0.3 0.4 0.3 0.3
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 131,680 149,792 150,845 152,842 167,485 183,557 254,390 316,033

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

Sales revenue

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

GL Pharma Vilnius - Social security debts

From To Debt, €
2026-01-16 2026-01-19 6224.75
2023-07-28 2023-08-01 3.42
2023-07-24 2023-07-25 3.54
2023-05-16 2023-05-17 3929.42

GL Pharma Vilnius - VMI tax arrears

From To Overdue, €
2025-04-14 2025-04-14 98.0

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
GL Pharma Vilnius, UAB (code 300621202) is a Private Limited Liability Company operating in market research and public opinion polling. In financial year 2025, the company generated revenue of €1.58M, up 6.5% year on year and 43.5% over two years. Net profit reached €58.9K, below the €89.8K achieved in 2024 but well above the €10.9K reported in 2023. This means profitability remained positive, although the profit margin eased to 3.7% from 6.0% in 2024. The 2025 result also reflects a stronger revenue base than in prior years, with steady expansion across the 2023–2025 period.

At year-end 2025, total assets amounted to €489.9K, supported by equity of €387.6K and liabilities of €110.9K. The equity ratio stood at 79.1%, and debt-to-equity was 0.29, indicating a conservative balance sheet structure. Return on equity was 15.2% and return on assets 12.0%. Asset turnover was 3.23x. With revenue per employee of €316.0K and profit per employee of €11.8K, the company showed solid operational productivity in 2025.